Biotechnology & Life Sciences Global On demand · 24-48h

Global Targeted NGS Amplicon Sequencing Services Market Strategic Research Report

Global Targeted NGS Amplicon Sequencing Services Market Stra…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Targeted NGS Amplicon Sequencing Services Market
$7682025
9.5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Blood Sample Sequencing, Tissue Sample Sequencing, Cell Sample Sequencing

By Application: Clinical Molecular Diagnostics, Human Genetics & Population Research, Agricultural Biotechnology & Breeding, Industrial Biotechnology, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: IDT, Azenta Life Sciences, Eurofins Genomics, Novogene, BGI (BGI Genomics), Macrogen, Psomagen, SeqMatic, CD Genomics, AllGenetics, Charles River, Source BioScience, AGRF, Plasmidsaurus, Eurofins Scientific, Charles River Laboratories, ABM, Zymo Research, Paragon Genomics, Quintara Bio, HyLabs, MUGTC, SeqCoast Genomics, Shanghai Baiqu Biomedical Technology, Illumina, Guangzhou IGE Biotechnology

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 162 pages
Market size 2025
$768
Million USD
Forecast CAGR
9.5%
2025-2032
Forecast 2032
$1449.6
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Targeted NGS Amplicon Sequencing Services market size is predicted to grow from US$ 768 million in 2025 to US$ 1,459 million in 2032; it is expected to grow at a CAGR of 9.5% from 2026 to 2032.

Targeted NGS Amplicon Sequencing is a targeted next-generation sequencing approach that first amplifies specific genomic regions of interest using polymerase chain reaction (PCR) to generate target amplicons, then performs high-throughput sequencing on these enriched fragments to analyze genetic variations efficiently. It focuses on predefined genomic loci such as disease-related genes, mutation hotspots or biomarker regions, bypassing whole-genome sequencing, delivering focused data output with high sequencing depth and accuracy, and enabling rapid detection of single nucleotide polymorphisms, insertions, deletions and other genetic variants.

Demand for targeted NGS amplicon sequencing is driven by the expansion of precision medicine, clinical genetic testing, infectious disease pathogen identification and agricultural genomic breeding, with stable clinical demand in oncology companion diagnostics, hereditary disease screening and microbial detection, and emerging demand in agricultural trait selection and environmental sample monitoring. Business opportunities lie in developing high-specificity amplicon panel design for rare diseases and drug resistance monitoring, optimizing library preparation workflows to reduce turnaround time and cost, launching integrated detection platforms for clinical and field applications, and expanding application scenarios in personalized health management and food safety testing.

This report presents a comprehensive overview of the global Targeted NGS Amplicon Sequencing Services market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Sample Type

  • Blood Sample Sequencing
  • Tissue Sample Sequencing
  • Cell Sample Sequencing

Segment by Target Region

  • Single-Gene Sequencing
  • Multi-Gene Panel Sequencing
  • Customized Region Sequencing

Segment by Sequencing Depth

  • Low-Depth Sequencing
  • Medium-Depth Sequencing
  • High-Depth Sequencing

Segment by Application

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Targeted NGS Amplicon Sequencing Services market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Clinical Molecular Diagnostics, Human Genetics & Population Research, Agricultural Biotechnology & Breeding evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Targeted NGS Amplicon Sequencing Services Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 9.5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$768
2025
Forecast
$1449.6
2032
CAGR
9.5%
2025–2032
Régions
5
global
Key companies
IDTAzenta Life SciencesEurofins GenomicsNovogeneBGI (BGI Genomics)MacrogenPsomagenSeqMatic
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Blood Sample SequencingTissue Sample SequencingCell Sample Sequencing
By Application
Clinical Molecular DiagnosticsHuman Genetics & Population ResearchAgricultural Biotechnology & BreedingIndustrial BiotechnologyOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Blood Sample Sequencing
  • 3.1.3 Tissue Sample Sequencing
  • 3.1.4 Cell Sample Sequencing
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Clinical Molecular Diagnostics
  • 4.1.3 Human Genetics & Population Research
  • 4.1.4 Agricultural Biotechnology & Breeding
  • 4.1.5 Industrial Biotechnology
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 IDT
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Azenta Life Sciences
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Eurofins Genomics
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Novogene
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 BGI (BGI Genomics)
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Macrogen
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Psomagen
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 SeqMatic
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 CD Genomics
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 AllGenetics
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Charles River
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Source BioScience
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 AGRF
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Plasmidsaurus
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Eurofins Scientific
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Charles River Laboratories
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 ABM
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Zymo Research
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Paragon Genomics
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Quintara Bio
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 HyLabs
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 MUGTC
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 SeqCoast Genomics
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Shanghai Baiqu Biomedical Technology
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Illumina
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Guangzhou IGE Biotechnology
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Targeted NGS Amplicon Sequencing Services market?
The global Targeted NGS Amplicon Sequencing Services market is estimated at US$ 768 million in 2025 (base year) and is projected to reach US$ 1.46 billion by 2032.
How fast is the Targeted NGS Amplicon Sequencing Services market expected to grow?
The market is expected to grow at a CAGR of 9.5% from 2026 to 2032, expanding from US$ 768 million in 2025 to US$ 1.46 billion in 2032, roughly 1.9 times its base-year value.
What does the Targeted NGS Amplicon Sequencing Services market cover?
Targeted NGS Amplicon Sequencing is a targeted next-generation sequencing approach that first amplifies specific genomic regions of interest using polymerase chain reaction (PCR) to generate target amplicons, then performs high-throughput sequencing on these enriched fragments to analyze genetic variations efficiently.
How is the Targeted NGS Amplicon Sequencing Services market segmented by sample type?
By sample type, the market is segmented into Blood Sample Sequencing, Tissue Sample Sequencing and Cell Sample Sequencing.
What are the key applications of Targeted NGS Amplicon Sequencing Services?
Key applications covered include Clinical Molecular Diagnostics, Human Genetics & Population Research, Agricultural Biotechnology & Breeding, Industrial Biotechnology and Others.
Which companies are profiled in the Targeted NGS Amplicon Sequencing Services market report?
Key players profiled include IDT, Azenta Life Sciences, Eurofins Genomics, Novogene, BGI (BGI Genomics), Macrogen, Psomagen and SeqMatic, among 26 companies covered in total.
What geographies does the Targeted NGS Amplicon Sequencing Services market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Targeted NGS Amplicon Sequencing Services?
Demand for targeted NGS amplicon sequencing is driven by the expansion of precision medicine, clinical genetic testing, infectious disease pathogen identification and agricultural genomic breeding, with stable clinical demand in oncology companion diagnostics, hereditary disease screening and microbial detection, and emerging demand in agricultural trait selection and environmental sample monitoring.
Who should buy the Targeted NGS Amplicon Sequencing Services market report?
The report is intended for manufacturers and solution providers, distributors and end users in Clinical Molecular Diagnostics, Human Genetics & Population Research and Agricultural Biotechnology & Breeding, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Targeted NGS Amplicon Sequencing Services market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.